What Gestational Diabetes Actually Does to the Placenta
What does gestational diabetes actually do to the placenta itself, beyond raising blood sugar numbers?
Gestational diabetes causes measurable structural and molecular changes in placental tissue — altered blood vessel development, disrupted gene expression at genes specifically involved in placentation, and shifts in the hormonal signals the placenta sends and receives — not just a blood sugar number that resolves once glucose is controlled. These changes are also increasingly linked to the child's own long-term metabolic health, not only to pregnancy-specific risks like macrosomia.
What happens to the placenta's blood vessels in gestational diabetes?
Most people assume a "stressed" placenta would be under-vascularized — fewer blood vessels, less blood flow. GDM placentas often show the opposite: they tend to be hypervascularized, meaning they develop more blood vessels than a typical placenta, not fewer. This isn't necessarily a sign of health; it appears to reflect abnormal angiogenic (blood vessel-forming) signaling rather than beneficial extra capacity.
Research has found that GDM placentas show increased activation of one VEGF receptor pathway (VEGFR2) alongside reduced expression of another (VEGFR1) — a shift in the balance of pro- and anti-angiogenic signaling that drives this excess, but poorly regulated, vessel growth. Separately, research has found impaired villous maturation in GDM placentas — the villi (the tree-like structures that form the actual exchange surface between maternal and fetal blood) don't develop with the same maturity pattern as in unaffected pregnancies, even when overall placental size and villous surface area look normal. There is one genuinely actionable finding within this research: a direct correlation has been demonstrated between how well maternal glucose is controlled and villous blood vessel area specifically — meaning glycemic control isn't just about avoiding a large baby, it's measurably connected to how well the placenta's own exchange architecture develops.
Does gestational diabetes change gene expression in the placenta?
Beyond blood vessels, GDM has been shown to alter the placental epigenome — changes to how genes are turned on and off, without changing the underlying DNA sequence itself. A genome-wide study comparing GDM and non-GDM placentas found over 12,000 differentially methylated regions, mapping to nearly 4,000 genes, with these changes concentrated in genes involved in Wnt and cadherin signaling — pathways specifically critical to placentation and early embryonic development. This represents a genuinely different category of change than a lab value fluctuating; it reflects the placenta's developmental program itself being altered at the molecular level in response to the maternal metabolic environment. It's the same class of mechanism we describe in our piece on how insulin resistance and PCOS affect the placenta, where the metabolic environment is already in place before conception.
Why might this matter beyond this pregnancy?
This is arguably the most important, underappreciated piece of this picture. A growing body of research under a framework called the Developmental Origins of Health and Disease (DOHaD) links a mother's metabolic environment during pregnancy — including GDM specifically — to a child's own future risk of obesity, metabolic syndrome, cardiovascular disease, and type 2 diabetes, well into adulthood. Fetoplacental vascular endothelial dysfunction — the kind of blood vessel signaling disruption described above — has specifically been proposed as an early, measurable marker connecting GDM exposure in utero to this later disease risk in the child. Our piece on what you can still control with a high-risk pregnancy covers practical steps relevant to managing this risk during pregnancy itself.
This isn't meant to add guilt to an already stressful diagnosis — GDM is common, and most of these mechanisms describe population-level associations and research findings, not a certainty for any individual pregnancy or child. It's meant to explain why active glycemic management during a GDM diagnosis is worth taking seriously as more than a short-term, resolve-after-delivery issue.
What does this mean practically?
The villous vessel area finding is genuinely worth holding onto: better glycemic control during a GDM pregnancy has a demonstrated, measurable connection to healthier placental vascular development, not just to birth weight or delivery complications. This reframes glycemic management as something that's actively shaping placental architecture in real time, which is a more concrete way to understand why consistent management matters, beyond just hitting a number on a glucose meter. Our piece on supporting a partner through gestational diabetes covers the practical, day-to-day side of this management, and patients across Long Island can work on it alongside their OB rather than instead of them.
The Bottom Line
Gestational diabetes changes the placenta itself — its blood vessel development, its villous maturation, and the expression of genes central to how it was built in the first place — through mechanisms that go well beyond a glucose number. The connection to a child's own long-term metabolic health through the DOHaD framework is a genuine, active area of research, not settled certainty, but it reframes glycemic management during GDM as something with real, structural stakes beyond the pregnancy itself. Here in Huntington, we talk through this fuller picture with patients navigating a GDM diagnosis, not just the day-to-day glucose targets. Our Metabolic & Immune Fertility Evaluation also supports patients addressing insulin resistance proactively before a future pregnancy, given how early these placental changes can begin.
This article is for general educational purposes and isn't a substitute for individualized guidance from your OB-GYN or maternal-fetal medicine specialist. Glycemic management decisions during gestational diabetes should be made directly with your care team.
East to West Fertility is a metabolic and immune-focused fertility clinic in Huntington, Long Island, serving patients across Long Island, NYC, and beyond. Learn more about our Metabolic & Immune Fertility Evaluation or call 631-416-4940.
References:
- "The Placenta in Gestational Diabetes: An Integrated Review on Metabolic Pathways, Genetic, Epigenetic and Ultrasound Biomarkers for Clinical Perspectives." PMC12842225.
- "Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1." PMC5560693.
- "Gestational diabetes mellitus placentas exhibit epimutations at placental development genes." PMC9665155.
- "Fetoplacental Vascular Endothelial Dysfunction as an Early Phenomenon in the Programming of Human Adult Diseases in Subjects Born from Gestational Diabetes Mellitus or Obesity in Pregnancy." PMC3226353.
- "The Hidden Impact of Gestational Diabetes: Unveiling Offspring Complications and Long-Term Effects." PMC11944258.
Related reading: what placental calcification on ultrasound actually means, and why the timing of the finding matters more than the grade number.
